Efavirenz and Sofosbuvir / velpatasvir (Epclusa 400 mg/100 mg Film Kaplı Tablet): interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Efavirenz induction reduces velpatasvir exposure.
Clinical significance and safety
Efavirenz may compromise sofosbuvir/velpatasvir hepatitis C treatment through reduced velpatasvir exposure. The label does not recommend coadministration; HIV and hepatitis teams should review the complete antiviral regimen.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.